TR200100207T2 - Apoptozun redüksiyonu için glükoz alımını kuvvetlendirici maddenin kullanıması - Google Patents

Apoptozun redüksiyonu için glükoz alımını kuvvetlendirici maddenin kullanıması

Info

Publication number
TR200100207T2
TR200100207T2 TR2001/00207T TR200100207T TR200100207T2 TR 200100207 T2 TR200100207 T2 TR 200100207T2 TR 2001/00207 T TR2001/00207 T TR 2001/00207T TR 200100207 T TR200100207 T TR 200100207T TR 200100207 T2 TR200100207 T2 TR 200100207T2
Authority
TR
Turkey
Prior art keywords
apoptosis
glucose uptake
reduction
human
enhancing glucose
Prior art date
Application number
TR2001/00207T
Other languages
English (en)
Turkish (tr)
Inventor
Michel Alain Bril Antoine
Edwin Buckingham Robin
Khandoudi Nassirah
Original Assignee
Smithkline Beecham P.L.C.
Smithkline Beecham Laboratoires Pharmacetiques S.A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9905387.8A external-priority patent/GB9905387D0/en
Application filed by Smithkline Beecham P.L.C., Smithkline Beecham Laboratoires Pharmacetiques S.A.S. filed Critical Smithkline Beecham P.L.C.
Publication of TR200100207T2 publication Critical patent/TR200100207T2/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TR2001/00207T 1998-07-21 1999-07-21 Apoptozun redüksiyonu için glükoz alımını kuvvetlendirici maddenin kullanıması TR200100207T2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GBGB9905387.8A GB9905387D0 (en) 1999-03-09 1999-03-09 Novel method

Publications (1)

Publication Number Publication Date
TR200100207T2 true TR200100207T2 (tr) 2001-05-21

Family

ID=27269407

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00207T TR200100207T2 (tr) 1998-07-21 1999-07-21 Apoptozun redüksiyonu için glükoz alımını kuvvetlendirici maddenin kullanıması

Country Status (25)

Country Link
EP (2) EP1516617A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2002521326A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20010079551A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1310620A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP2001002036A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE288746T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU5053799A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG105250A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9912117A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2338211A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69923687T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1098639T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA200100165A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2237929T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUP0103199A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (1) ID26986A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL140664A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO20010292L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA11579A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL345627A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1098639E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1098639T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK1012001A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR200100207T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2000004890A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3073600A (en) * 1999-01-19 2000-08-07 Sankyo Company Limited Inhibitor for nerve cell death due to glutamic acid cytotoxicity
ES2204684T3 (es) * 1999-08-27 2004-05-01 Eli Lilly And Company Derivados de biaril-oxa(tia)zol y su uso como modulares de ppar.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2137915T3 (es) * 1987-09-04 2000-01-01 Beecham Group Plc Derivados de tiazolidindiona sustituida.
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
WO1998010760A1 (fr) * 1996-09-12 1998-03-19 Sankyo Company, Limited Potentialisateur d'activite de glutathione-reductase contenant de la troglitazone
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
ATE325607T1 (de) * 1997-11-19 2006-06-15 Takeda Pharmaceutical Aptoptoseinhibitoren
AU2781899A (en) * 1998-02-24 1999-09-15 Trustees Of The University Of Pennsylvania, The Use of a cardiac purinoceptor to effect cellular glucose uptake
AU4005299A (en) * 1998-05-19 1999-12-06 Regents Of The University Of California, The Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
EP1516617A2 (en) 2005-03-23
HUP0103199A2 (hu) 2002-05-29
DE69923687D1 (de) 2005-03-17
NO20010292D0 (no) 2001-01-18
BR9912117A (pt) 2001-04-10
NO20010292L (no) 2001-03-08
SK1012001A3 (en) 2001-08-06
DE69923687T2 (de) 2006-04-06
ID26986A (id) 2001-02-22
PT1098639E (pt) 2005-06-30
EP1098639B1 (en) 2005-02-09
BG105250A (en) 2001-11-30
EA200100165A1 (ru) 2001-08-27
AU5053799A (en) 2000-02-14
ES2237929T3 (es) 2005-08-01
AP2001002036A0 (en) 2001-03-31
SI1098639T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2005-08-31
ATE288746T1 (de) 2005-02-15
EP1098639A1 (en) 2001-05-16
OA11579A (en) 2004-06-01
PL345627A1 (en) 2002-01-02
DK1098639T3 (da) 2005-06-13
IL140664A0 (en) 2002-02-10
CN1310620A (zh) 2001-08-29
CA2338211A1 (en) 2000-02-03
JP2002521326A (ja) 2002-07-16
WO2000004890A1 (en) 2000-02-03
HK1037865A1 (en) 2002-02-22
HUP0103199A3 (en) 2002-08-28
KR20010079551A (ko) 2001-08-22

Similar Documents

Publication Publication Date Title
Cohen The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease
IL142824A0 (en) Lipoic acid derivatives and their use in treatment of disease
AU1929199A (en) Methods for the recovery and measurement of troponin complexes
TR199902608T2 (xx) Bo�az yumu�at�c� bile�imler.
IT8921086A0 (it) Protesi vascolare contenente nella parete microcapsule inglobanti cellule produttrici di ormoni.
WO2000061192A3 (en) Methods and compositions for the treatment of pancreatitis
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
AU3221599A (en) Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
BR0007785B1 (pt) composiÇço em barra de limpeza de pele.
TR199701365T1 (xx) Bir k�lot bile�eni ve bir emici pedi haiz hijyenik k�lot.
EP0811078A4 (en) Bcr-abl directed compositions and uses for inhibiting philadelphia chromosome stimulated cell growth
ITBO930075A0 (it) Tramoggia per elementi allungati,in particolare articoli da fumo.
BR0010708A (pt) Glicosìdeos androgênicos e atividade androgênica dos mesmos
AU2003216517A1 (en) Iliac bifurcation balloon catheter
TR200100207T2 (tr) Apoptozun redüksiyonu için glükoz alımını kuvvetlendirici maddenin kullanıması
AR004494A1 (es) Una celula util para el tratamiento del dolor, un metodo para producirla, un organo bioartificial de la comprende y un metodo para preparar dicho organobioartificial
ITTV970088A0 (it) Struttura calzabile sportiva e metodi per attuare la stessa in partico lare per pattini monofilari e da shortracking.
MY111718A (en) Deuterated active substances in transdermal application
TR200003357T2 (tr) Efervesan preparatlar.
DK1135169T3 (da) Anvendelse af et farmaceutisk præparat indeholdende et anticancermiddel og mindst et peptid.
ATE203674T1 (de) Verwendung eines extraktes von alchemilla vulgaris
ZA992406B (en) Use of sulodexide and of the medicines containing it in the treatment of the diabetic retinopathy.
WO2001051093A3 (en) METHODS OF INCREASING THE GLUCOSE RESPONSIVENESS OF PANCREATIC β-CELLS
ECSP993063A (es) Nuevo metodo para reducir o prevenir la apoptosis de celulas diferenciadas
DE69110861D1 (de) Mittel zur verbesserung des kollagenmetabolismus und dessen verwendung.